Status:
UNKNOWN
Study of CM310 in Subjects With Seasonal Allergic Rhinitis
Lead Sponsor:
Keymed Biosciences Co.Ltd
Conditions:
Seasonal Allergic Rhinitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is a multicenter, single arm phase II clinical study mainly evaluating the efficacy of CM310 in patients with seasonal allergic rhinitis.
Detailed Description
Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.
Eligibility Criteria
Inclusion
- Male or female aged 18-65.
- Understand the study and sign the Informed Consent Form voluntarily.
- Take effective contraception measures throughout the study period.
Exclusion
- Used other investigational drugs.
- Allergies to drugs with IL-4Rα monoclonal antibody or drug components of CM310.
- Plan to participate in other studies during this clinical trial.
- With malignant or benign tumors of the nasal cavity.
- Other reasons the researcher believes that the subject is not suitable to participate in this study.
Key Trial Info
Start Date :
March 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06171074
Start Date
March 30 2024
End Date
March 30 2025
Last Update
December 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tong-Ren hospital
Beijing, China